Not a good buy right now for an impatient entry: price is extended short-term (RSI elevated) and sitting near resistance, while analyst sentiment has deteriorated.
Trend is currently bullish, but risk/reward at $23.81 is unfavorable versus nearby resistance (~$24.18) and likely mean-reversion after a sharp move.
If you already own: hold into strength rather than add here; if you must initiate now, it’s a lower-conviction buy with limited near-term upside and higher pullback risk.
Trend/Momentum: MACD histogram is positive (0.205) and expanding, indicating bullish momentum remains intact.
Overbought/Stretch: RSI(6) at 76.761 signals the move is stretched; pullback risk is elevated after the recent run.
Moving averages: Converging MAs suggest the trend is improving but not in a clean, strong uptrend yet.
Key levels: Pivot 22.747 (first important support). Resistance levels: R1 23.631 (already exceeded) and R2 24.178 (next ceiling). A push toward R2 is possible, but upside is limited before hitting resistance.
Pattern-based odds: Similar-pattern projection implies slight weakness near-term (next day/week) and modest improvement over a month (+2.12%), consistent with “near-term cool-off then stabilize.”
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning: Open interest put/call ratio at 0.77 leans modestly bullish (more calls than puts outstanding).
Activity: Extremely low options volume today (2 contracts; put volume 0) makes sentiment inference weak; this is not a high-conviction options tape.
Volatility: 30D IV 68.12 vs historical vol 34.85 suggests options are pricing elevated uncertainty; IV rank 25.44 / percentile 47.01 is mid-range (not extreme).
Technical Summary
Sell
6
Buy
7
Positive Catalysts
with solid revenue and earnings growth, which can support the stock on dips.
if buyers persist.
Neutral/Negative Catalysts
Wall Street sentiment has weakened: multiple price-target cuts and a notable downgrade (Goldman Buy -> Neutral) citing 2026 headwinds.
Headwinds flagged by analysts: below-target treatment volume growth, partial reversal of 2025 benefits (phosphate binders), potential ACA subsidy expiry impacts, and incremental training costs.
No near-term news catalysts: “No news in recent week” reduces the probability of a fresh event-driven leg higher.
Short-term technical risk: RSI is elevated and price is near resistance, increasing odds of a pullback versus an immediate clean breakout.
Profitability: Net income 321,187,167.81 (+37.23% YoY) and EPS 1.1 (+37.50% YoY) — earnings growth outpacing revenue, indicating margin/efficiency improvement.
Gross margin: 25.43 (+5.61% YoY) — positive margin trend supports the quality of earnings.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: Clear downward revisions in January 2026—multiple banks cut price targets; Goldman downgraded to Neutral; Morgan Stanley and JPMorgan remain Underweight.
Latest notable calls:
Goldman Sachs (2026-01-20): Downgrade to Neutral, PT cut to EUR 40 from EUR 55; highlights several FY26 headwinds.
Citi (2026-01-23): PT cut to EUR 39.50 from EUR 48.50; keeps Neutral.
Deutsche Bank (2026-01-26): PT cut to EUR 44 from EUR 46; keeps Hold.
Morgan Stanley (2026-01-27): PT cut to EUR 36 from EUR 37; keeps Underweight.
Cons: FY26 operational/regulatory cost and demand headwinds, and skepticism about achieving medium-term volume outlook.
Influential/political trading check: No recent congress trading data available; insider and hedge fund activity flagged as neutral with no significant recent trends.
Wall Street analysts forecast FMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FMS is 25 USD with a low forecast of 22 USD and a high forecast of 28 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast FMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FMS is 25 USD with a low forecast of 22 USD and a high forecast of 28 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
1 Sell
Moderate Sell
Current: 24.350
Low
22
Averages
25
High
28
Current: 24.350
Low
22
Averages
25
High
28
Morgan Stanley
Aisyah Noor
Underweight
downgrade
AI Analysis
2026-01-27
Reason
Morgan Stanley
Aisyah Noor
Price Target
AI Analysis
2026-01-27
downgrade
Underweight
Reason
Morgan Stanley analyst Aisyah Noor lowered the firm's price target on Fresenius Medical to EUR 36 from EUR 37 and keeps an Underweight rating on the shares.
Deutsche Bank
Hold
downgrade
2026-01-26
Reason
Deutsche Bank
Price Target
2026-01-26
downgrade
Hold
Reason
Deutsche Bank lowered the firm's price target on Fresenius Medical to EUR 44 from EUR 46 and keeps a Hold rating on the shares.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for FMS
